A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).

Chisholm, Julia; Casanova, M.; Geoerger, Birgit; Merks, Johannes H. M.; Massimini, Giorgio; Moore, Nicholas; Rooney, Isabelle; Viviers, Louis; Oberlin, O.

doi:10.1200/jco.2010.28.15_suppl.tps330

Search citation statements

Order By: Relevance

Paper Sections

Select...

New Agents Against Rms1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2020

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On this basis, RMS experts in Europe are focusing their attention on the use of bevacizumab, a recombinant humanized monoclonal antibody targeting VEGF. The EpSSG/ITCC 'Bernie' protocol is randomizing metastatic RMS patients to receive IVADo plus maintenance chemotherapy versus the same regimen plus bevacizumab [66].…”

Section: New Agents Against Rmsmentioning

confidence: 99%